Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Descovy Approved As Second HIV Prevention Drug Despite Ongoing Controversies October 4, 2019 Irvin Jackson Add Your Comments Federal drug regulators have approved the drug Descovy as a treatment to prevent the spread of HIV, providing an alternative to Truvada, which has been the only HIV PrEP drug available on the market, and has been linked to concerns about potential side effects associated with long-term use. In a press release issued this week, the FDA announced that Descovy has been approved as an HIV-1 pre-exposure prophylaxis (PrEP), which can be used by individuals at risk of contracting HIV infections from most forms of sex. However, the FDA cautions that Descovy has not been approved to help prevent HIV in those who receive receptive vaginal sex, indicating the drug’s effectiveness has not been tested in that situation. HIV DRUGS LAWSUITS Did you suffer kidney injuries or bone fractures on Truvada or other TDF-based HIV drugs? Gilead HIV drugs Truvada, Atripla, Stribild, Viread and Complera have been linked to increased risks of kidney and bones injuries, which lawsuits allege may have been avoided if safer formulations had not been withheld by the manufacturer. Learn More SEE IF YOU QUALIFY FOR COMPENSATION HIV DRUGS LAWSUITS Did you suffer kidney injuries or bone fractures on Truvada or other TDF-based HIV drugs? Gilead HIV drugs Truvada, Atripla, Stribild, Viread and Complera have been linked to increased risks of kidney and bones injuries, which lawsuits allege may have been avoided if safer formulations had not been withheld by the manufacturer. Learn More SEE IF YOU QUALIFY FOR COMPENSATION “PrEP drugs are highly effective when taken as indicated in the drug labeling and can prevent HIV infection,” Dr. Jeffrey Murray, deputy director of the Division of Antiviral Products in the FDA’s Center for Drug Evaluation and Research, said in the press release. “This approval provides more prevention options for certain patients at-risk for acquiring HIV and helps further efforts by the FDA and the U.S. Department of Health and Human Services to facilitate the development of HIV treatment and prevention options to reduce new HIV infections.” Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) was developed by Gilead, which also manufactures Truvada and other widely used HIV drugs that are part of an older class of antivirals known as tenofovir disoproxil fumarate (TDF). Side effects of TDF HIV drugs have been linked to an increased risk of bone fractures, kidney injury and other side effects. However, in recent years, the drug maker has introduced Descovy and other medications that are part of a newer class of antivirals known as tenofovir alafenamide (TAF), which are generally safer and less toxic. This expanded approval of Descovy, which allows Gilead to promote the newer drug for HIV PrEP, comes as the drug maker was facing an approaching end of patent protection for Truvada, which will allow generic competitors to market the older treatment. Over the past few years, Gilead has faced a number of Truvada lawsuits, alleging that the manufacturer intentionally withheld the safer TAF drugs for years, extending the period of patent protection that will allow the drug maker to market their HIV drugs without generic competition. Plaintiffs allege that they suffered bone fractures, serious kidney problems and other injuries from Truvada, Atripla, Stribild and other TDF drugs, indicating that they may have avoided these injuries if Gilead had not intentionally delayed the development and approval of safer TAF-based drugs. According to allegations raised in the lawsuits, Gilead knew that TAF was a safer alternative design, which allows delivery of the active ingredient at much lower doses. Although TAF development first started around 2004, the drug maker did not take steps to bring the safer design to market until 2015, as Truvada and other TDF drugs were nearing the end of patent protection. Tags: Descovy, Gilead, HIV, HIV Drug, Truvada Image Credit: | More HIV Drugs Lawsuit Stories Gilead Settles HIV Drug Lawsuit Over Patent on Truvada and Descovy January 20, 2025 U.S. Government Files Appeal Over Gilead Truvada, Descovy HIV Drug Patents July 10, 2024 Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M June 12, 2024 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES 6 Bard PowerPort Lawsuits Selected for Bellwether Trials in Federal MDL (Posted: today) A federal judge has identified the six Bard PowerPort lawsuits that will serve as the first bellwether trials, to test allegations that the port catheters were defectively designed. MORE ABOUT: BARD POWERPORT LAWSUITCourt Indicates Bard PowerPort MDL Bellwether Lawsuits Should Include 3 Infection, 2 Thrombosis and 1 Fracture Case (05/06/2025)Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (04/30/2025)Bard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025) MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 3 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025) Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: 4 days ago) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)
6 Bard PowerPort Lawsuits Selected for Bellwether Trials in Federal MDL (Posted: today) A federal judge has identified the six Bard PowerPort lawsuits that will serve as the first bellwether trials, to test allegations that the port catheters were defectively designed. MORE ABOUT: BARD POWERPORT LAWSUITCourt Indicates Bard PowerPort MDL Bellwether Lawsuits Should Include 3 Infection, 2 Thrombosis and 1 Fracture Case (05/06/2025)Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (04/30/2025)Bard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025)
MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 3 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)
Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: 4 days ago) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)